CN111820395A - Production method of fine monosodium glutamate - Google Patents
Production method of fine monosodium glutamate Download PDFInfo
- Publication number
- CN111820395A CN111820395A CN202010714088.9A CN202010714088A CN111820395A CN 111820395 A CN111820395 A CN 111820395A CN 202010714088 A CN202010714088 A CN 202010714088A CN 111820395 A CN111820395 A CN 111820395A
- Authority
- CN
- China
- Prior art keywords
- liquor
- monosodium glutamate
- mixed
- membrane separator
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 title claims abstract description 28
- 235000013923 monosodium glutamate Nutrition 0.000 title claims abstract description 28
- 239000004223 monosodium glutamate Substances 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 27
- 238000000855 fermentation Methods 0.000 claims abstract description 20
- 230000004151 fermentation Effects 0.000 claims abstract description 20
- 239000012528 membrane Substances 0.000 claims abstract description 20
- 239000003513 alkali Substances 0.000 claims abstract description 19
- 239000011259 mixed solution Substances 0.000 claims abstract description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 7
- PHKGGXPMPXXISP-DFWYDOINSA-N azanium;(4s)-4-amino-5-hydroxy-5-oxopentanoate Chemical compound [NH4+].[O-]C(=O)[C@@H]([NH3+])CCC([O-])=O PHKGGXPMPXXISP-DFWYDOINSA-N 0.000 claims abstract description 7
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 7
- 239000004220 glutamic acid Substances 0.000 claims abstract description 7
- 235000013917 monoammonium glutamate Nutrition 0.000 claims abstract description 7
- 239000000047 product Substances 0.000 claims abstract description 7
- 235000018102 proteins Nutrition 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000000084 colloidal system Substances 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 238000005406 washing Methods 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229930003316 Vitamin D Natural products 0.000 claims description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 8
- 239000004227 calcium gluconate Substances 0.000 claims description 8
- 229960004494 calcium gluconate Drugs 0.000 claims description 8
- 235000013927 calcium gluconate Nutrition 0.000 claims description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 8
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 8
- 235000013928 guanylic acid Nutrition 0.000 claims description 8
- 239000004226 guanylic acid Substances 0.000 claims description 8
- 235000019166 vitamin D Nutrition 0.000 claims description 8
- 239000011710 vitamin D Substances 0.000 claims description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 8
- 229940046008 vitamin d Drugs 0.000 claims description 8
- 239000011576 zinc lactate Substances 0.000 claims description 8
- 229940050168 zinc lactate Drugs 0.000 claims description 8
- 235000000193 zinc lactate Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 4
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 4
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 4
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims description 4
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 4
- 235000016491 selenocysteine Nutrition 0.000 claims description 4
- 229940055619 selenocysteine Drugs 0.000 claims description 4
- 229960002718 selenomethionine Drugs 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000012670 alkaline solution Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 4
- 229940024606 amino acid Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940073490 sodium glutamate Drugs 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- -1 seleno-amino acid Chemical compound 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 3
- 235000013919 monopotassium glutamate Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000007645 potassium deficiency Diseases 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- BQXFQDOHKMTBDK-UHFFFAOYSA-N cysteinyl radical Chemical compound [S]CC(N)C(O)=O BQXFQDOHKMTBDK-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/21—Synthetic spices, flavouring agents or condiments containing amino acids
- A23L27/22—Synthetic spices, flavouring agents or condiments containing amino acids containing glutamic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/23—Synthetic spices, flavouring agents or condiments containing nucleotides
- A23L27/235—Synthetic spices, flavouring agents or condiments containing nucleotides containing also amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
- A23L27/24—Synthetic spices, flavouring agents or condiments prepared by fermentation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a production method of fine monosodium glutamate, which comprises the following steps: step one, mycelium, solid protein and colloid in fermentation liquor containing glutamic acid or ammonium glutamate are blocked in a membrane separator; step two, washing residues remained in the membrane separator by using the rinse water, and mixing the rinse water with the filtrate obtained in the step one to obtain a mixed solution one; slowly adding an alkali liquor mixed by sodium hydroxide and potassium hydroxide into the mixed liquor I, and continuously stirring, wherein the hydroxide concentration of the alkali liquor is 0.1mol/L, simultaneously detecting the pH value of the mixed liquor by using a pH tester, and stopping adding the alkali liquor until the pH value is 7 to obtain a mixed liquor II; and step four, transferring the mixed solution II to a vacuum distiller for concentration to obtain finished product crystals. The invention is beneficial to keeping certain freshness and simultaneously is beneficial to ensuring the health of human body.
Description
Technical Field
The invention belongs to the technical field of food, and particularly relates to a production method for fine monosodium glutamate.
Background
The sodium glutamate is the common monosodium glutamate in daily life of people, is a crystalline substance separated as a flavoring component, and is called a chemical flavoring agent.
Excessive ingestion of sodium glutamate tends to increase the sodium content in the body. The sodium element is also an important induction factor for chronic diseases such as hypertension, cardiovascular diseases, diabetes, nephritis and the like. If the food is not taken, the experience feeling in the process of eating is poor, and partial nutrition deficiency, body discomfort and other diseases can be caused due to insufficient intake.
Disclosure of Invention
The invention aims to solve the technical problems in the prior art and provides a production method for fine monosodium glutamate, which can improve the delicious degree of real objects and is beneficial to the health of human bodies.
The invention is realized by the following technical scheme: a production method for fine monosodium glutamate comprises the following steps:
step one, sending fermentation liquor containing glutamic acid or ammonium glutamate into a membrane separator, and blocking mycelium, solid protein and colloid in the fermentation liquor in the membrane separator;
step two, washing residues remained in the membrane separator by using the rinse water, and mixing the rinse water and the filtrate obtained in the step one to obtain a mixed solution one;
slowly adding an alkali liquor mixed by sodium hydroxide and potassium hydroxide into the mixed liquor I obtained in the second step, and continuously stirring, wherein the hydroxide concentration of the alkali liquor is 0.1mol/L, simultaneously detecting the pH value of the mixed liquor by using a pH tester, and stopping adding the alkali liquor until the pH value is 7 to obtain a mixed liquor II;
and step four, transferring the mixed solution II to a vacuum distiller for concentration, thereby obtaining finished product crystals.
Further, the molar ratio of sodium hydroxide to potassium hydroxide in the alkali liquor is 24-46: 1.
further, the temperature of the vacuum distiller in the fourth step is 63-85 ℃, and the vacuum degree is 33-45 Kpa.
Further, in the first step, before the fermentation liquor is sent to the membrane separator, the fermentation liquor is heated to 68-77 ℃.
And further adding zinc lactate, guanylic acid, calcium gluconate, seleno-amino acid, vitamin C and vitamin D into the mixed solution II obtained in the step three.
Furthermore, the percentage of the total amount of the alkali liquor is 0.1 to 0.13 percent of zinc lactate, 0.04 to 0.1 percent of guanylic acid, 0.07 to 0.1 percent of calcium gluconate, 0.01 to 0.02 percent of seleno-amino acid, 0.12 to 0.15 percent of vitamin C and 0.07 to 0.12 percent of vitamin D.
Further, the seleno-amino acid can be one or a mixture of two of selenomethionine and selenocysteine.
Further, in the step one, before the fermentation liquor is added into the membrane separator, activated carbon is added into the fermentation liquor for adsorption treatment.
The invention has the following beneficial effects:
1. the alkali liquor is composed of sodium hydroxide and potassium hydroxide, and the monosodium glutamate prepared by the method is mainly a mixture of sodium glutamate and potassium glutamate, so that certain freshness can be kept, and the health of a human body can be guaranteed.
2. And the second mixed solution is concentrated by using a vacuum distillation mode, so that the efficiency of monosodium glutamate can be improved, partial substances in the second mixed solution can be prevented from being oxidized, and the generated ammonium hydroxide can be removed conveniently.
3. Before the second concentration, the second concentration is carried out, the trace nutrients are added, so that the second concentration is beneficial to supplementing substances required by a human body, and the calcium element and the potassium element are also beneficial to balancing the sodium element by the human body, so that the second concentration is beneficial to relieving diseases of hypertension, cardiovascular disease and the like of the human body.
Detailed Description
The invention is realized by the following technical scheme: a production method for fine monosodium glutamate comprises the following steps:
step one, sending fermentation liquor containing glutamic acid or ammonium glutamate into a membrane separator, and blocking mycelium, solid protein and colloid in the fermentation liquor in the membrane separator;
step two, washing residues remained in the membrane separator by using the rinse water, and mixing the rinse water and the filtrate obtained in the step one to obtain a mixed solution one;
slowly adding an alkali liquor mixed by sodium hydroxide and potassium hydroxide into the mixed liquor I obtained in the second step, and continuously stirring, wherein the hydroxide concentration of the alkali liquor is 0.1mol/L, simultaneously detecting the pH value of the mixed liquor by using a pH tester, and stopping adding the alkali liquor until the pH value is 7 to obtain a mixed liquor II;
and step four, transferring the mixed solution II to a vacuum distiller for concentration, thereby obtaining finished product crystals.
By adopting the technical scheme, the main components of the monosodium glutamate produced in the way are sodium glutamate and potassium glutamate, so that the intake of sodium element can be reduced under the condition of ensuring certain freshness, and the diseases such as hypertension, cardiovascular disease, diabetes, nephritis and the like can be reduced.
Meanwhile, potassium has the main functions of maintaining acid-base balance, participating in energy metabolism and maintaining normal functions of neuromuscular system in human body. When potassium deficiency occurs in vivo, general weakness, fatigue, heart beat weakening, dizziness and dim eyesight can be caused, and severe potassium deficiency can also cause paralysis and death of respiratory muscles. In addition, low potassium levels slow gastrointestinal motility, leading to enteroparalysis, exacerbation of anorexia, and symptoms of nausea, vomiting, abdominal distension, and the like. Therefore, the increase of the intake of potassium is not only beneficial to regulating and controlling the balance of sodium and potassium in human bodies, but also can relieve various adverse symptoms caused by potassium deficiency.
In addition, the generated ammonium hydroxide can be rapidly removed in an ammonia gas mode in the vacuum distillation process, thereby being beneficial to improving the purity of the monosodium glutamate.
Further, the molar ratio of sodium hydroxide to potassium hydroxide in the alkali liquor is 24-46: 1.
further, the temperature of the vacuum distiller in the fourth step is 63-85 ℃, and the vacuum degree is 33-45 Kpa.
By adopting the technical scheme, the vacuum distillation can accelerate the concentration rate of the second mixed solution and is also beneficial to reducing the contact between the second mixed solution and the air, thereby being beneficial to reducing the probability of oxidizing the glutamate and further reducing the content of impurities in the final finished product.
Further, in the first step, before the fermentation liquor is sent to the membrane separator, the fermentation liquor is heated to 68-77 ℃.
By adopting the technical scheme, the glutamic acid or the ammonium glutamate can be ensured to be dissolved in the fermentation liquor. When the fermentation liquid is filtered in the membrane separator, glutamic acid and ammonium glutamate can be fully separated from mycelium, solid protein and colloid, and the yield of glutamic acid or ammonium glutamate is further improved.
And further adding zinc lactate, guanylic acid, calcium gluconate, seleno-amino acid, vitamin C and vitamin D into the mixed solution II obtained in the step three.
By adopting the technical scheme, zinc lactate, guanylic acid, calcium gluconate, seleno-amino acid, vitamin C and vitamin D are all trace elements required by a human body, and the trace elements of the human body can be effectively supplemented by adding the zinc lactate, guanylic acid, calcium gluconate, seleno-amino acid, vitamin C and vitamin D into monosodium glutamate. In addition, vitamin D is beneficial to the absorption of calcium element by human body, and after the human body supplements sufficient calcium element, the diseases of hypertension, cardiovascular disease and the like caused by excessive sodium intake are relieved.
Furthermore, the percentage of the total amount of the alkali liquor is 0.1 to 0.13 percent of zinc lactate, 0.04 to 0.1 percent of guanylic acid, 0.07 to 0.1 percent of calcium gluconate, 0.01 to 0.02 percent of seleno-amino acid, 0.12 to 0.15 percent of vitamin C and 0.07 to 0.12 percent of vitamin D.
By adopting the technical scheme, excessive vitamin C is added, so that in the high-temperature cooking process, the vitamin C can protect other nutrient substances and reduce the problem of denaturation of other substances.
Further, the seleno-amino acid can be one or a mixture of two of selenomethionine and selenocysteine.
By adopting the technical scheme, selenium is ingested in a mode of selenomethionine and selenocysteine, so that on one hand, the requirement of a human body on selenium element can be ensured, on the other hand, methionine radical and cysteine radical are also easily converted into corresponding amino acid by the human body, and then required substances are provided for synthesizing protein by human body cells.
Further, in the step one, before the fermentation liquor is added into the membrane separator, activated carbon is added into the fermentation liquor for adsorption treatment.
By adopting the technical scheme, the obtained fermentation liquor generally contains some pigments and large-particle impurities, so that the problems of incomplete finished products and blockage of a membrane separator are easily caused in the processes of finished product preparation and membrane separation respectively, and the problems can be just solved by the activated carbon, so that the quality and the production efficiency of the monosodium glutamate are improved.
The invention has the following beneficial effects:
1. the alkali liquor is composed of sodium hydroxide and potassium hydroxide, and the monosodium glutamate prepared by the method is mainly a mixture of sodium glutamate and potassium glutamate, so that certain freshness can be kept, and the health of a human body can be guaranteed.
2. And the second mixed solution is concentrated by using a vacuum distillation mode, so that the efficiency of monosodium glutamate can be improved, partial substances in the second mixed solution can be prevented from being oxidized, and the generated ammonium hydroxide can be removed conveniently.
3. Before the second concentration, the second concentration is carried out, the trace nutrients are added, so that the second concentration is beneficial to supplementing substances required by a human body, and the calcium element and the potassium element are also beneficial to balancing the sodium element by the human body, so that the second concentration is beneficial to relieving diseases of hypertension, cardiovascular disease and the like of the human body.
Claims (8)
1. A production method for fine monosodium glutamate is characterized by comprising a furnace body;
step one, sending fermentation liquor containing glutamic acid or ammonium glutamate into a membrane separator, and blocking mycelium, solid protein and colloid in the fermentation liquor in the membrane separator;
step two, washing residues remained in the membrane separator by using the rinse water, and mixing the rinse water and the filtrate obtained in the step one to obtain a mixed solution one;
slowly adding an alkali liquor mixed by sodium hydroxide and potassium hydroxide into the mixed liquor I obtained in the second step, and continuously stirring, wherein the hydroxide concentration of the alkali liquor is 0.1mol/L, simultaneously detecting the pH value of the mixed liquor by using a pH tester, and stopping adding the alkali liquor until the pH value is 7 to obtain a mixed liquor II;
and step four, transferring the mixed solution II to a vacuum distiller for concentration, thereby obtaining finished product crystals.
2. The production method of fine monosodium glutamate according to claim 1, wherein the molar ratio of sodium hydroxide to potassium hydroxide in the alkaline solution is 24-46: 1.
3. the method for producing refined monosodium glutamate as claimed in claim 1, wherein the temperature of the vacuum distiller in the fourth step is 63-85 ℃, and the vacuum degree is 33-45 Kpa.
4. The method for producing refined monosodium glutamate as claimed in claim 1, wherein the fermentation broth is heated to 68-77 ℃ before being fed to the membrane separator in the first step.
5. The method for producing essence monosodium glutamate according to claim 1, wherein zinc lactate, guanylic acid, calcium gluconate, selenoamino acid, vitamin C and vitamin D are added to the mixed solution II of the step three.
6. The production process of claim 1, wherein the alkali solution includes zinc lactate 0.1-0.13 wt%, guanylic acid 0.04-0.1 wt%, calcium gluconate 0.07-0.1 wt%, seleno-amino acid 0.01-0.02 wt%, vitamin C0.12-0.15 wt% and vitamin D0.07-0.12 wt%.
7. The method for producing essence of monosodium glutamate according to claim 1, wherein the seleno-amino acid is one or a mixture of selenomethionine and selenocysteine.
8. The method for producing refined monosodium glutamate according to claim 1, wherein in the first step, the fermentation broth is added with activated carbon for adsorption before being added into the membrane separator.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010714088.9A CN111820395A (en) | 2020-07-23 | 2020-07-23 | Production method of fine monosodium glutamate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010714088.9A CN111820395A (en) | 2020-07-23 | 2020-07-23 | Production method of fine monosodium glutamate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111820395A true CN111820395A (en) | 2020-10-27 |
Family
ID=72926230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010714088.9A Withdrawn CN111820395A (en) | 2020-07-23 | 2020-07-23 | Production method of fine monosodium glutamate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111820395A (en) |
-
2020
- 2020-07-23 CN CN202010714088.9A patent/CN111820395A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010220630A (en) | Method for preparing calcium gluconate | |
CN103911416B (en) | Method for preparing active peptide from scallop skirts | |
CN101724675A (en) | Process for preparing albumin polypeptide | |
CN110818752B (en) | Process for producing lactitol | |
CN107198252B (en) | Silkworm pupa protein, compound protein thereof and preparation method thereof | |
CN114134189B (en) | Method for synchronously producing low-calorie syrup containing trehalose and erythritol | |
CN111820395A (en) | Production method of fine monosodium glutamate | |
CN104366611A (en) | Purple sweet potato nutritive fruit juice | |
CN109457008B (en) | Preparation method of ginseng chelating peptide | |
CN111838535A (en) | Highland barley functional red yeast rice rich in ergosterol and preparation method thereof | |
CN1476782A (en) | Preparation process of complete-component pearl product | |
CN109984192B (en) | Preparation method of condensed milk with caramel taste | |
CN102342400A (en) | High-calcium xylitol | |
CN114190534B (en) | Preparation method of low-sodium composite salty agent and product obtained by preparation method | |
CN104365848A (en) | Purple sweet potato milk tea and preparation method thereof | |
CN101863789A (en) | Method for separation and purification of L-potassium glutamate monohydrate | |
LU503470B1 (en) | METHOD FOR MANUFACTURING RICE BRAN FOOD RICH IN γ-AMINOBUTYRIC ACID (GABA) | |
CN115886188A (en) | Method for producing instant oat flour by using maltitol | |
CN114317635A (en) | Method for preparing low-density digestion-resistant starch | |
CN106616842A (en) | Zinc-rich seasoning | |
CN107177653B (en) | Method for preparing blood sugar reducing peptide by utilizing needle mushroom | |
CN117397810A (en) | DHA algae oil special dietary drink and preparation method thereof | |
JPH0113352B2 (en) | ||
CN117866803A (en) | Monosodium glutamate production method | |
CN109123606A (en) | A kind of selected rice is manufactured to mix reconciliation syrup and its manufacturing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201027 |